LOS ANGELES, April 26, 2019 (GLOBE NEWSWIRE) -- The global Recombinant Plasma Protein Therapeutics Market size is estimated to grow at CAGR above 8.3 % over the forecast time frame 2019-2026 and reach the market value around USD 17.1 billion by 2026.
It is expected that plasma derived protein will be replaced by recombinant plasma products, the number of products being launched will be increased, and demand for new therapies for hemophilia therapy will increase.
Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1308
Segment Insights
Based on drug class, cell line and indications, the worldwide recombinant plasma protein treatment market has been broken down. Based on the class of the medicines, recombinant clotting and human esterase inhibitors have been classified in the market. A further subsegment of recombinant coagulation factor VIII, recombinant factor IX, recombinant factor VIIa and others was found in the segment of re-combinant coagulatory factors. Recombinant coagulation factor VIII is projected by 2027, due to an increase in homophile A cases worldwide, new product launches and the utilization of recombinant plasma protein therapy for treating Hemophilia A, to make a major portion of the recombinant coagulation factor segment in the market by 2026. The VIIa sub-segment of the recombinant coagulation factor is expected to expand steadily over the forecast period. The Chinese hamster ovary cells (CHO), the baby kidney (BHK), the human embryonic kidney (HEK) cells, and more were categorized as a cell line in the market. Increased utilization of CHO cell lines for the production of therapeutic products is expected to expand to a prominent CAGR in the Chinese cell line (CHO). Based on indication, hemophilia B, hemophilia A, von Willebrand and others were separated from the market.
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/recombinant-plasma-protein-therapeutics-market
Regional Outlook
The market will be driven by the rise in the numbers of rare hematology diseases in Asia-Pacific, by the increase in recombinant DNA technology for therapeutic use and by increased R&D spending by companies in pharmaceuticals and biotechnology. In addition, in Japan and China, a growth opportunity is created in the market for recombinant coagulation factors of the third generation. Government and NGOs are currently trying to raise awareness of hemophilia A and B and help the general population understand the cases, diagnoses, and methods of treatment for rare diseases. Currently, with regulatory authorities, countries like China, Japan, Australia and New Zealand have been converted to hemophilia A standard recombinant plasma therapy. 80 percent of patients with bleeding chaos are treated with recombinant coagulation factors according to the Hemophilia Foundation Australia (HFA). Therefore, an increase in recombinant therapies is projected to drive the market during the predicted period for hemophilia treatment.
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
Key Players and Strategies
The Recombinant Plasma Protein Therapeutics market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Bayer AG, Novo Nordisk A / S, Aptevo Therapeutics, Octapharma, Pharma Group NV, Bioverativ Therapeutics, Inc. (Sanofi),Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others.
These companies are able to expand their global market presence through new product launch, purchasing, geographical expansion, collaborations and distribution agreements. Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, was acquired by Shire in January 2019. This acquisition aims to strengthen the geographic presence of Takeda Pharmaceutical Company Limited. Bioverativ Therapeutics Inc., which operates as part of Sanofi Genzyme, has been acquired by Sanofi, the leading pharmaceutical company, in January 2018. Many other players on the market have also taken steps to expand their business in emerging markets. Leading players in the Asia Pacific, such as China, Japan and Australia, also concentrate on increasing their customer base. Market participants are also supporting several campaigns to increase awareness about hematological disorder and the availability and advantages offered by such products of treatments, such as recombinant plasma proteins.
INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1308
The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1308
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting/
Browse More Press Releases: http://www.amecoresearch.com/press-releases